Pharsight

Mydayis patents expiration

MYDAYIS Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6913768 TAKEDA PHARMS USA Sustained release delivery of amphetamine salts
May, 2023

(4 months ago)

US9173857 TAKEDA PHARMS USA Controlled dose drug delivery system
May, 2026

(2 years from now)

US8846100 TAKEDA PHARMS USA Controlled dose drug delivery system
Aug, 2029

(5 years from now)

Mydayis is owned by Takeda Pharms Usa.

Mydayis contains Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate.

Mydayis has a total of 3 drug patents out of which 1 drug patent has expired.

Expired drug patents of Mydayis are:

  • US6913768

Mydayis was authorised for market use on 20 June, 2017.

Mydayis is available in capsule, extended release;oral dosage forms.

Mydayis can be used as treatment of attention deficit hyperactivity disorder.

The generics of Mydayis are possible to be released after 24 August, 2029.

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity (PED) Mar 13, 2023

Drugs and Companies using AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE ingredient

Market Authorisation Date: 20 June, 2017

Treatment: Treatment of attention deficit hyperactivity disorder

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of MYDAYIS before it's drug patent expiration?
More Information on Dosage

MYDAYIS family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic